Evidence map›Paper›PMID 39869907›Full record

ArticleJMIR formative research2025

Methods to Adjust for Confounding in Test-Negative Design COVID-19 Effectiveness Studies: Simulation Study.

Elizabeth Ak Rowley, Patrick K Mitchell, Duck-Hye Yang, Ned Lewis, Brian E Dixon, Gabriela Vazquez-Benitez, William F Fadel, Inih J Essien, Allison L Naleway, Edward Stenehjem and 8 more

Abstract read
In one paragraph

Article in JMIR formative research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elizabeth Ak RowleyWestat, Rockville, MD, United States.ORCID 0000-0002-0593-1096
Patrick K MitchellWestat, Rockville, MD, United States.ORCID 0000-0001-6848-0846
Duck-Hye YangWestat, Rockville, MD, United States.ORCID 0009-0006-3493-1550
Ned LewisVaccine Study Center, Northern California Division of Research, Kaiser Permanente, Oakland, CA, United States.ORCID 0009-0003-1862-3062
Brian E DixonCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, United States.ORCID 0000-0002-1121-0607
Gabriela Vazquez-BenitezHealthPartners Institute, Minneapolis, MN, United States.ORCID 0000-0002-6226-3207
William F FadelCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, United States.ORCID 0000-0002-0292-6734
Inih J EssienHealthPartners Institute, Minneapolis, MN, United States.ORCID 0000-0003-0775-8255
Allison L NalewayCenter for Health Research, Kaiser Permanente, Portland, OR, United States.ORCID 0000-0001-5747-4643
Edward StenehjemDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, UT, United States.ORCID 0000-0001-6065-9964
Toan C OngDepartment of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.ORCID 0000-0001-6787-1407
Manjusha GaglaniDepartment of Pediatrics, Section of Pediatric Infectious Diseases, Baylor Scott & White Health, Temple, TX, United States.ORCID 0000-0002-3952-9230
Karthik NatarajanDepartment of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, United States.ORCID 0000-0002-9066-9431
Peter EmbiCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, United States.ORCID 0000-0002-7733-0847
Ryan E WiegandNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.ORCID 0000-0002-9486-1850
Ruth Link-GellesNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.ORCID 0000-0002-9617-806X
Mark W TenfordeNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.ORCID 0000-0002-8702-8393
Bruce FiremanVaccine Study Center, Northern California Division of Research, Kaiser Permanente, Oakland, CA, United States.ORCID 0000-0003-1652-985X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReal-world COVID-19 vaccine effectiveness (VE) studies are investigating exposures of increasing complexity accounting for time since vaccination. These studies require methods that adjust for the confounding that arises when morbidities and demographics are associated with vaccination and the risk of outcome events. Methods based on propensity scores (PS) are well-suited to this when the exposure is dichotomous, but present challenges when the exposure is multinomial.

objectiveThis simulation study aimed to investigate alternative methods to adjust for confounding in VE studies that have a test-negative design.

methodsAdjustment for a disease risk score (DRS) is compared with multivariable logistic regression. Both stratification on the DRS and direct covariate adjustment of the DRS are examined. Multivariable logistic regression with all the covariates and with a limited subset of key covariates is considered. The performance of VE estimators is evaluated across a multinomial vaccination exposure in simulated datasets.

resultsBias in VE estimates from multivariable models ranged from -5.3% to 6.1% across 4 levels of vaccination. Standard errors of VE estimates were unbiased, and 95% coverage probabilities were attained in most scenarios. The lowest coverage in the multivariable scenarios was 93.7% (95% CI 92.2%-95.2%) and occurred in the multivariable model with key covariates, while the highest coverage in the multivariable scenarios was 95.3% (95% CI 94.0%-96.6%) and occurred in the multivariable model with all covariates. Bias in VE estimates from DRS-adjusted models was low, ranging from -2.2% to 4.2%. However, the DRS-adjusted models underestimated the standard errors of VE estimates, with coverage sometimes below the 95% level. The lowest coverage in the DRS scenarios was 87.8% (95% CI 85.8%-89.8%) and occurred in the direct adjustment for the DRS model. The highest coverage in the DRS scenarios was 94.8% (95% CI 93.4%-96.2%) and occurred in the model that stratified on DRS. Although variation in the performance of VE estimates occurred across modeling strategies, variation in performance was also present across exposure groups.

conclusionsOverall, models using a DRS to adjust for confounding performed adequately but not as well as the multivariable models that adjusted for covariates individually.

Indexed as

COVID-19COVID-19 VaccinesResearch DesignVaccine EfficacyComputer SimulationConfounding Factors, EpidemiologicHumansLogistic ModelsPropensity ScoreSARS-CoV-2COVID-19 VaccinesassessmentcomorbidityCOVID-19disease risk scorepropensity scoresimulation studyusefulnessvaccine effectiveness

Identifiers

PMID39869907
PMCPMC11811671

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.